Paul Peter Tak | Senior Vice President of Research and Development Pipeline and Chief Immunology Officer

Paul Peter Tak, Senior Vice President of Research and Development Pipeline and Chief Immunology Officer, GSK

Paul-Peter Tak is Senior Vice President (SVP) R&D Pipeline, Chair of the Development Steering Team and Chief Immunology Officer at GSK. He is global head of R&D for Oncology, ImmunoInflammation, Infectious Disease and Dermatology. He is also on the Board of Directors of ViiV Healthcare and Galvani Bioelectronics.

He received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has worked as a scientist at the University of California San Diego for two years. He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years.  He has published extensively in peer-reviewed scientific journals (H factor 105). He is a Fellow of the Academy of Medical Sciences.

In addition to his work in academia he was the co-founder and member of the Board of Directors of MediPartners  bv in Leiden (first commercial Industrial Medicine Company in the Netherlands) from 1991 to 1997. He established a biotech company developing intra-articular gene therapy (Arthrogen b.v., Amsterdam) and served as its Chief Scientific Officer from 2005 until 2015. He was Medical Director of the Dubai Bone and Joint Centre from 2004 until 2008.


Precision 2018 Day 2 @ 09:00

Towards prevention of autoimmune disease: the example of rheumatoid arthritis

  • Predictors for rheumatoid arthritis (RA) development will be presented
  • PRAIRI study is the first evaluating the effects of a biopharmaceutical in subjects at risk of developing RA
  • A single infusion of 1000 mg rituximab delays the development of arthritis up to 12 months

Precision 2018 Day 2 @ 09:25

Stories from AstraZeneca’s innovative medicines and early development biotech unit

  • Quality, not quantity: Improving productivity by implementation of a company-wide framework and a precision approach
  • A success story of precision medicine in oncology and moving into other therapy areas – identifying the right target, in the right patients, at the right time for the best outcome to improve patients’ lives
  • Identifying new drug targets following a genomic approach across all therapy areas

Precision 2018 Day 2 @ 11:40

Roundtable discussion session

This roundtable session will run as two, 30 minute rotations, enabling you to join 2 roundtables of your choice

Table 3: Biohacking in precision medicine

back to speakers

Sign Up for Event Updates

World Precision Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Joan Shutt
t/ +44 (0)207 092 1134


Issa Mauthoor
+44 (0)207 092 1257